Effects of human alveolar macrophages on the induction of lymphokine (IL 2)-activated killer cells.
Open Access
- 1 July 1987
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 139 (1) , 29-34
- https://doi.org/10.4049/jimmunol.139.1.29
Abstract
Normal human alveolar macrophages (AM) significantly and reproducibly suppress induction of IL 2-activated killer (LAK) cell activity against allogeneic Burkitt's lymphoma (Daudi) cells. Incubation of purified peripheral blood lymphocytes for 4 days with autologous AM and 1 U/ml of IL 2 resulted in AM-mediated suppression of LAK activity, whereas peripheral blood monocytes isolated freshly by centrifugal elutriation from the same donor potentiated induction of LAK activity by IL 2. The suppression of LAK cell induction by human AM was dependent on the density of AM added to the lymphocyte cultures. Recombinant IFN-gamma did not affect AM-mediated suppression of LAK cell induction by IL 2. Both AM and monocytes stimulated with lipopolysaccharide markedly suppressed LAK cell induction by IL 2. AM-mediated down-regulation was seen only when AM were added immediately after the start of incubation of lymphocytes with IL 2; AM potentiated LAK activity when added 1 day later. Similar AM-mediated suppression of LAK cell induction was observed with four lines of allogeneic lung cancer cells as targets for LAK activity. These results indicate that AM may be important in regulation of in situ induction of LAK activity in the lung.This publication has 24 references indexed in Scilit:
- Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cellsThe Journal of Experimental Medicine, 1983
- Translation of interleukin 2 mRNA from human peripheral blood leukocytes in Xenopus oocytesBiochemical and Biophysical Research Communications, 1982
- Human alveolar macrophages: potentiation of their tumoricidal activity by liposome-encapsulated muramyl dipeptide.The Journal of Immunology, 1982
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982
- INVITRO GENERATION OF TUMORICIDAL PROPERTIES IN HUMAN ALVEOLAR MACROPHAGES FOLLOWING INTERACTION WITH ENDOTOXIN1982
- Induction of cytotoxic activity in human lymphocytes against autologous and allogeneic melanoma cells in vitro by culture with interleukin 2International Journal of Cancer, 1981
- Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide.Proceedings of the National Academy of Sciences, 1981
- ACTIVATION OF RAT ALVEOLAR MACROPHAGES TO THE TUMORICIDAL STATE IN THE PRESENCE OF PROGRESSIVELY GROWING PULMONARY METASTASES1981
- Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages.The Journal of Immunology, 1980
- LYMPHOPROLIFERATIVE RESPONSES TO ANTIGENS MEDIATED BY HUMAN PULMONARY ALVEOLAR MACROPHAGES1977